Two clinical studies report using 99mTc radiolabeled TNF-α mAb infliximab for scintigraphy imaging to both monitor refractory sarcoidosis disease activity and evaluate potential patient response to anti-TNF-α treatment (126, 127). Here, TNF is linked to sarcoidosis.